187 related articles for article (PubMed ID: 31586008)
1. Alteration of Cellular Reduction Potential Will Change
Floberg JM; Wang L; Bandara N; Rashmi R; Mpoy C; Garbow JR; Rogers BE; Patti GJ; Schwarz JK
J Nucl Med; 2020 Mar; 61(3):427-432. PubMed ID: 31586008
[TBL] [Abstract][Full Text] [Related]
2. Cellular Uptake of the ATSM-Cu(II) Complex under Hypoxic Conditions.
Walke GR; Meron S; Shenberger Y; Gevorkyan-Airapetov L; Ruthstein S
ChemistryOpen; 2021 Apr; 10(4):486-492. PubMed ID: 33908707
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.
Hueting R; Kersemans V; Cornelissen B; Tredwell M; Hussien K; Christlieb M; Gee AD; Passchier J; Smart SC; Dilworth JR; Gouverneur V; Muschel RJ
J Nucl Med; 2014 Jan; 55(1):128-34. PubMed ID: 24337603
[TBL] [Abstract][Full Text] [Related]
4. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
6. 64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.
Li F; Jørgensen JT; Forman J; Hansen AE; Kjaer A
J Nucl Med; 2016 Mar; 57(3):437-43. PubMed ID: 26585061
[TBL] [Abstract][Full Text] [Related]
7. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
Dietz DW; Dehdashti F; Grigsby PW; Malyapa RS; Myerson RJ; Picus J; Ritter J; Lewis JS; Welch MJ; Siegel BA
Dis Colon Rectum; 2008 Nov; 51(11):1641-8. PubMed ID: 18682881
[TBL] [Abstract][Full Text] [Related]
8. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
9. Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.
Handley MG; Medina RA; Mariotti E; Kenny GD; Shaw KP; Yan R; Eykyn TR; Blower PJ; Southworth R
J Nucl Med; 2014 Mar; 55(3):488-94. PubMed ID: 24421288
[TBL] [Abstract][Full Text] [Related]
10. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
12. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation.
Yoshii Y; Yoneda M; Ikawa M; Furukawa T; Kiyono Y; Mori T; Yoshii H; Oyama N; Okazawa H; Saga T; Fujibayashi Y
Nucl Med Biol; 2012 Feb; 39(2):177-85. PubMed ID: 22033022
[TBL] [Abstract][Full Text] [Related]
13. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
14. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.
Grigsby PW; Malyapa RS; Higashikubo R; Schwarz JK; Welch MJ; Huettner PC; Dehdashti F
Mol Imaging Biol; 2007; 9(5):278-83. PubMed ID: 17431727
[TBL] [Abstract][Full Text] [Related]
15. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.
Lewis JS; Laforest R; Dehdashti F; Grigsby PW; Welch MJ; Siegel BA
J Nucl Med; 2008 Jul; 49(7):1177-82. PubMed ID: 18552145
[TBL] [Abstract][Full Text] [Related]
16. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
17. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.
Vāvere AL; Lewis JS
Nucl Med Biol; 2008 Apr; 35(3):273-9. PubMed ID: 18355682
[TBL] [Abstract][Full Text] [Related]
18. Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.
Bonnitcha PD; Bayly SR; Theobald MB; Betts HM; Lewis JS; Dilworth JR
J Inorg Biochem; 2010 Feb; 104(2):126-35. PubMed ID: 19932509
[TBL] [Abstract][Full Text] [Related]
19. Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.
Nie X; Randolph GJ; Elvington A; Bandara N; Zheleznyak A; Gropler RJ; Woodard PK; Lapi SE
Nucl Med Biol; 2016 Sep; 43(9):534-542. PubMed ID: 27372286
[TBL] [Abstract][Full Text] [Related]
20. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
